Achyut Healthcar

Why is Achyut Healthcare Ltd falling/rising?

As of 31-Aug, Achyut Healthcare Ltd's stock price is currently at 6.79, reflecting a recent decline despite positive long-term performance. The drop in investor participation and short-term price momentum suggests ongoing weakness in the stock's performance.

As of 31-Aug, Achyut Healthcare Ltd's stock price is falling, currently at 6.79, which reflects a decrease of 0.16 or 2.3%. This decline is occurring despite the stock's positive performance over longer periods, such as a 4.78% increase over the past month and a significant 23.45% rise year-to-date. However, the stock has experienced a recent downturn, with a 3.00% drop over the last week, contrasting with a minor decline of 0.53% in the Sensex during the same period.<BR><BR>Today's trading activity indicates that the stock's performance is in line with its sector, but there are concerning signs regarding investor participation. The delivery volume on August 28 was 11.54k, which represents a substantial decrease of 70.45% compared to the 5-day average delivery volume. This drop in investor participation may contribute to the stock's price decline, as lower trading volumes can indicate reduced interest or confidence among investors.<BR><BR>Additionally, while the stock's price is above the 100-day and 200-day moving averages, it is below the 5-day, 20-day, and 50-day moving averages, suggesting a short-term weakness in price momentum. Overall, the combination of declining investor participation and recent price movements contributes to the current downward trend in Achyut Healthcare Ltd's stock price.

Who are in the management team of Achyut Healthcar?

The management team of Achyut Healthcar includes Jigen Jagdishbhai Modi (Managing Director & CFO), Mahendra C Raycha (Chairman & Non-Executive Director), Akshit Raycha (Non-Executive Director), Amisha Jigen Modi (Executive Director), and independent directors Rutvik Sanjaykumar Thakkar and Sonu Lalitkumar Jain.

The management team of Achyut Healthcar includes the following individuals:<BR><BR>1. **Jigen Jagdishbhai Modi** - Managing Director & CFO<BR>2. **Mahendra C Raycha** - Chairman & Non-Executive Director<BR>3. **Akshit Raycha** - Non-Executive Director<BR>4. **Amisha Jigen Modi** - Executive Director<BR>5. **Rutvik Sanjaykumar Thakkar** - Independent Non-Executive Director<BR>6. **Sonu Lalitkumar Jain** - Independent Non-Executive Director<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

What does Achyut Healthcar do?

Achyut Healthcare Ltd operates in the Pharmaceuticals & Biotechnology sector as a Micro Cap company, with recent quarterly net sales of 3 Cr and a net profit of 0 Cr. The company has a market cap of INR 162 Cr and a P/E ratio of 523.00.

Overview:<BR>Achyut Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Achyut Healthcare Limited was incorporated as 'Achyut Securities Private Limited' in 1996 and later changed its name to 'Achyut Healthcare Private Limited' in 2002. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 162 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 523.00<BR>- Industry P/E: 21<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.09<BR>- Return on Equity: 0.91%<BR>- Price to Book: 4.78<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Achyut Healthcar?

Achyut Healthcar's peers include Brooks Lab, CCME Global, Syschem (India), Smruthi Organic, Parnax Lab, Panch.Organics, Auro Labs, and Quest Laborato. The company has a 1-year return of 35.80%, with varying management risks and capital structures among its peers.

Peers: The peers of Achyut Healthcar are Brooks Lab., CCME Global, Syschem (India), Smruthi Organic, Parnax Lab, Panch.Organics, Auro Labs., and Quest Laborato.<BR><BR>Quality Snapshot: Below Average management risk is observed at Brooks Lab., CCME Global, Syschem (India), and the rest. Average management risk is found at Smruthi Organic and Panch.Organics, while Excellent management risk is noted at Parnax Lab. Good growth is seen at Syschem (India), CCME Global, and Parnax Lab., while Average growth is attributed to Achyut Healthcar, and Below Average growth is noted at Brooks Lab., Smruthi Organic, and the rest. Achyut Healthcar and Syschem (India) have a Good capital structure, while Excellent capital structure is observed at Parnax Lab. and Panch.Organics, with Below Average capital structure at Brooks Lab. and Auro Labs.<BR><BR>Return Snapshot: Achyut Healthcar has a 1-year return of 35.80%, which is higher than the lowest peer, CCME Global, with an undefined return, and lower than the highest peer, Guj. Inject(Ker), with a return of 406.91%. Additionally, Syschem (India), Panch.Organics, and Auro Labs. have negative six-month returns.

How big is Achyut Healthcar?

As of 31st August, Achyut Healthcare Ltd has a market capitalization of 162.00 Cr, with recent net sales of 11.64 Cr and a net profit of 0.32 Cr. The company reported shareholder's funds of 31.30 Cr and total assets of 32.58 Cr for the annual period ending in March 2025.

As of 31st August, Achyut Healthcare Ltd has a market capitalization of 162.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Achyut Healthcare reported Net Sales of 11.64 Cr and a Net Profit of 0.32 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds amounting to 31.30 Cr and Total Assets of 32.58 Cr.

Which are the latest news on Achyut Healthcar?

Should I buy, sell or hold Achyut Healthcare Ltd?

When is the next results date for Achyut Healthcare Ltd?

The next results date for Achyut Healthcare Ltd is 13 August 2026.

The next results date for Achyut Healthcare Ltd is scheduled for 13 August 2026.

Are Achyut Healthcare Ltd latest results good or bad?

Achyut Healthcare Ltd's latest results show significant growth in net sales and profit, but concerns about thin profit margins, revenue volatility, and high valuation suggest an unfavorable outlook. Investors should be cautious, as risks may outweigh the positives.

Achyut Healthcare Ltd's latest results present a mixed picture. On one hand, the company reported a significant quarter-on-quarter increase in both net sales and net profit for Q4 FY26, with net sales rising by 179.62% to ₹4.39 crores and net profit increasing by 500% to ₹0.06 crores. This dramatic growth might seem promising at first glance.<BR><BR>However, a deeper analysis reveals serious concerns. The company's profit margins are extremely thin, with a PAT margin of just 1.37% and an operating profit margin of only 0.68%. Such low margins indicate that the core pharmaceutical operations are not generating meaningful profitability. Additionally, the company's return on equity (ROE) stands at a mere 1.74%, which is among the lowest in the sector, highlighting weak capital efficiency.<BR><BR>The volatility in revenue is alarming, with sales fluctuating significantly from quarter to quarter, suggesting instability in the business model. For instance, the previous quarter (Q3 FY26) saw a decline in sales by 38.43% from Q2 FY26. This inconsistency raises questions about the company's operational stability.<BR><BR>Furthermore, the valuation metrics are concerning. Achyut Healthcare trades at a P/E ratio of 250.57, which is extraordinarily high compared to industry peers, indicating that the market may be overvaluing the stock relative to its financial performance.<BR><BR>In summary, while the latest results show some positive growth figures, the underlying profitability issues, revenue volatility, and extreme valuation suggest that the overall outlook for Achyut Healthcare is not favorable. Investors should approach with caution, as the risks appear to outweigh the positives.

How has been the historical performance of Achyut Healthcar?

Achyut Healthcar's historical performance shows fluctuating financial metrics, with net sales peaking at 6.14 Cr in March 2024 before declining to 3.05 Cr in March 2025. The company maintained a zero-debt status while experiencing operating losses and an increase in total liabilities and assets during this period.

Answer:<BR>The historical performance of Achyut Healthcar shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Achyut Healthcar's net sales have varied significantly, with a peak of 6.14 Cr in March 2024, followed by a decline to 3.05 Cr in March 2025. The total operating income mirrored this trend, reaching 6.14 Cr in March 2024 and dropping to 3.05 Cr in March 2025. The company experienced operating losses, with an operating profit (PBDIT) of 0.72 Cr in March 2025, slightly down from 0.76 Cr in March 2024. Profit before tax also showed a slight decrease from 0.74 Cr in March 2024 to 0.70 Cr in March 2025, while profit after tax increased from 0.50 Cr to 0.55 Cr during the same period. The total liabilities rose from 30.95 Cr in March 2024 to 32.58 Cr in March 2025, reflecting an increase in trade payables and current liabilities. Total assets also increased from 30.95 Cr to 32.58 Cr, primarily driven by growth in current assets, which amounted to 12.06 Cr in March 2025, down from 21.47 Cr in March 2024. The company maintained a zero-debt status throughout the years, indicating no long-term or short-term borrowings.

Who are the top shareholders of the Achyut Healthcar?

The top shareholders of Achyut Healthcar include Mahendra C Raycha Huf as the largest promoter with 10.21%, and Dharm Prakash Tripathi as the highest public shareholder at 16.26%. Individual investors hold 39.82% of shares, while foreign institutional investors account for 8.14%, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Achyut Healthcar include a mix of promoters and public investors. The majority shareholders are the promoters, with Mahendra C Raycha Huf being the promoter with the highest holding at 10.21%. The highest public shareholder is Dharm Prakash Tripathi, who holds 16.26%. Additionally, individual investors collectively hold 39.82% of the shares, while foreign institutional investors (FIIs) hold 8.14% through three different entities. There are no pledged promoter holdings, and no mutual funds are involved in the company's shareholding.

Is Achyut Healthcar overvalued or undervalued?

As of May 30, 2025, Achyut Healthcar is considered a risky investment due to its overvaluation indicated by a PE ratio of 82.45, negative operational efficiency ratios, and poor returns on capital and equity, despite a recent positive stock return.

As of 30 May 2025, Achyut Healthcar's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company is currently deemed overvalued, particularly highlighted by its PE ratio of 82.45, which is substantially higher than peers like MMTC Ltd. at 119.39 and Optiemus Infracom Ltd. at 82.35. Additionally, Achyut's EV to EBIT and EV to EBITDA ratios are both at -82.07, suggesting severe operational inefficiencies.<BR><BR>The company's ROCE stands at -0.72% and ROE at 1.79%, further underscoring its struggles in generating returns for shareholders. Compared to its peers, Achyut Healthcar's valuation metrics are concerning, especially when juxtaposed with PTC India Ltd., which has a PE ratio of just 9.02 and is classified as very attractive. Despite a recent positive stock return of 5.11% over the past week compared to the Sensex's 1.37%, the overall trend indicates that Achyut Healthcar remains a risky investment, with its long-term performance trailing behind the broader market.

What is the technical trend for Achyut Healthcar?

As of April 23, 2025, Achyut Healthcar's trend is mildly bearish, with mixed signals from indicators like the MACD, Bollinger Bands, and moving averages, suggesting some positive momentum but overall weakness.

As of 23 April 2025, the technical trend for Achyut Healthcar has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, suggesting some positive momentum, while the monthly MACD is mildly bearish, indicating a potential longer-term weakness. The Bollinger Bands are signaling a mildly bearish stance on both weekly and monthly time frames. Daily moving averages also reflect a mildly bearish trend. The Dow Theory shows no trend on the weekly chart but is mildly bullish on the monthly, which adds some complexity to the overall view. The RSI shows no signals on both time frames, indicating a lack of momentum. Overall, the current stance is mildly bearish with mixed signals across different indicators.

What is the bonus history of the Achyut Healthcar?

Achyut Healthcare's recent bonus history includes a 4:10 ratio announced on December 10, 2024, and a 1:2 ratio issued on April 25, 2023.

Achyut Healthcare has a notable bonus history. The most recent bonus issue was a 4:10 ratio announced for December 10, 2024. Prior to that, on April 25, 2023, the company issued a bonus in a 1:2 ratio. If you have any more questions about the company or its financial activities, feel free to ask!

Has Achyut Healthcar declared dividend?

No Dividend History Available